Skip to main content

Table 4 Sensitivity analyses of the clinical risk score

From: Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study

  Clinical Risk Score
Moderate + High Risk (≥ 4) High Risk (≥ 6)
Value 95% CI Value 95% CI
Sensitivity 0.19 0.09–0.36 0.17 0.03–0.49
Specificity 0.92 0.84–0.97 0.89 0.82–0.94
Positive predictive value 0.50 0.24–0.76 0.14 0.03–0.44
Negative predictive value 0.74 0.64–0.81 0.91 0.84–0.95